Discover
TSBX
Turnstone Biologics Corp.
0.35
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | ||
| 1y |
0.35
day range
0.35
0.40
52 week range
5.75
| Open | 0.35 | Prev Close | 0.35 | Low | 0.35 | High | 0.35 | Mkt Cap | 10.46M |
| Vol | 283.77K | Avg Vol | 273.99K | EPS | -2.28 | P/E | N/A | Forward P/E | -0.19 |
| Beta | N/A | Short Ratio | 1.03 | Inst. Own | 60.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.50 | 200-d Avg | 1.76 | 1yr Est | 2.38 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.87 | -0.74 | 0.13 | 14.94% |
| 2024-08-14 | 2024-06 | -0.84 | -0.92 | -0.08 | -9.52% |
| 2024-08-14 | 2024-06 | -0.84 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.78 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.78 | -0.85 | -0.07 | -8.97% |
| 2024-03-21 | 2023-12 | -0.86 | -0.73 | 0.13 | 15.12% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-10-14 | B of A Securities | Downgrade | Buy | Neutral |
| 2024-08-19 | B of A Securities | Upgrade | Buy | Buy |
| 2024-08-19 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2023-08-15 | B of A Securities | Upgrade | Buy | |
| 2023-08-15 | Piper Sandler | Upgrade | Overweight |
Profile
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-07-24 | FMR LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2023-07-19 | GUPTA RISHI | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2023-07-24 | JEREL DAVIS C | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2023-07-19 | ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Orbimed Advisors LLC. | 3.10M | 1.40M | 13.40% |
| 2024-09-29 | FMR, LLC | 1.17M | 530.31K | 5.07% |
| 2024-09-29 | Pfm Health Sciences, Lp | 932.35K | 421.51K | 4.03% |
| 2024-09-29 | Point72 Asset Management, L.P. | 932.23K | 421.46K | 4.03% |
| 2024-09-29 | Bank of America Corporation | 911.74K | 412.20K | 3.94% |
| 2024-09-29 | Citadel Advisors Llc | 689.21K | 311.59K | 2.98% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 495.07K | 223.82K | 2.14% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 86.30K | 39.01K | 0.37% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 83.40K | 37.71K | 0.36% |
| 2024-10-30 | iShares Micro Cap ETF | 38.34K | 17.33K | 0.17% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 20.45K | 9.24K | 0.09% |
| 2024-10-30 | Fidelity Total Market Index Fund | 14.82K | 6.70K | 0.06% |